论文部分内容阅读
随机公开对照试验收治12例心律失常患儿,包括隐匿性附加旁路(CAP)4例,预激综合征(WPW)3例,希氏束心动过速(HBT)2例和室性心动过速(VT)3例。其中10例是曾用胺碘酮等其它抗心律失常药失效的患儿。7 例一次静注氟卡胺(flecainide)20-100mg,随后每日口服75-300mg本品10-39mo;其他5例病儿以口服治疗。结果CAP2例与3例WPW中2例恢复窦性节律,HBT2例减慢了心率,但仅1例恢复窦性心律。口
Randomized open-label controlled trials included 12 children with arrhythmia, including 4 cases of occult accessory bypass (CAP), 3 cases of WPW (3), 2 cases of His bundle tachycardia (HBT) and 2 cases of ventricular tachycardia (VT) in 3 cases. Of these, 10 were those who had failed with other antiarrhythmic drugs such as amiodarone. 7 cases of a intravenous flecainide (flecainide) 20-100mg, followed by daily oral administration of 75-300mg of this product 10-39mo; the other 5 cases of children to oral treatment. Results Two cases of CAP2 and three cases of WPW regains sinus rhythm, while HBT2 slowed heart rate, but only one case recovered sinus rhythm. mouth